Chimeric Antigen Receptor T Cells Show Efficacy in Multiple Myeloma But Pose Toxicity and Safety Concerns

Strategic Insights -

Researchers from the Icahn School of Medicine at Mount Sinai published a study evaluating 213 patients with myeloma treated with B-cell maturation antigen-directed CAR-T cells. The study found that prolonged hematologic toxicity remains a common adverse event, and secondary myeloid malignancies are a significant safety concern. The research also revealed that patients with persistent grade 3 neutropenia or thrombocytopenia at day 100 had shorter progression-free survival and overall survival.

Key Takeaways:

  • The study evaluated 213 patients with myeloma treated with B-cell maturation antigen-directed CAR-T cells, highlighting the efficacy of CAR-T cells but also the associated toxicities.
  • Prolonged hematologic toxicity was found to be a common adverse event, with 19% of patients experiencing grade 3 neutropenia or thrombocytopenia at day 100.
  • The presence of persistent grade 3 neutropenia or thrombocytopenia at day 100 was associated with shorter progression-free survival and overall survival.
  • The research suggested a potential role of CAR-T in influencing TP53 clonal dynamics and myeloid disease development.
  • The study was supported by the National Cancer Institute, National Institutes of Health, Multiple Myeloma Research Foundation, Bristol Myers Squibb Foundation, Conquer Cancer Foundation, and ECOG-ACRIN Cancer Research Group.
  • The research has been peer-reviewed and published in Clinical Cancer Research, a leading journal in the field of cancer research.

Statistics:

  • 213 patients with myeloma were treated with B-cell maturation antigen-directed CAR-T cells.
  • 19% of patients (40 individuals) experienced persistent grade 3 neutropenia or thrombocytopenia at day 100.
  • Patients with persistent grade 3 neutropenia or thrombocytopenia at day 100 had a significantly shorter progression-free survival (P = 0.0003) and overall survival (P < 0.99).
  • The study underscored the impact of hematologic toxicity and clonal hemopoiesis on B-cell maturation antigen CAR-T outcomes.

Sources:

  • Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy. Clinical Cancer Research, 2025;31(20):4333-4344.
  • Researchers' Work from Icahn School of Medicine at Mount Sinai Focuses on Hematopoiesis (Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric ...). Hematology Week. October 27, 2025; p 727.